- Home
- EMN vs SNN Comparison
EMN vs SNN Comparison
Compare EMN & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMN
- SNN
- Stock Information
- Founded
- EMN 1920
- SNN 1856
- Country
- EMN United States
- SNN United Kingdom
- Employees
- EMN N/A
- SNN N/A
- Industry
- EMN Major Chemicals
- SNN Industrial Specialties
- Sector
- EMN Industrials
- SNN Health Care
- Exchange
- EMN Nasdaq
- SNN Nasdaq
- Market Cap
- EMN 12.9B
- SNN 10.8B
- IPO Year
- EMN 1993
- SNN 1999
- Fundamental
- Price
- EMN $101.59
- SNN $24.88
- Analyst Decision
- EMN Buy
- SNN Strong Buy
- Analyst Count
- EMN 14
- SNN 1
- Target Price
- EMN $111.50
- SNN N/A
- AVG Volume (30 Days)
- EMN 1.0M
- SNN 962.8K
- Earning Date
- EMN 10-31-2024
- SNN 08-01-2024
- Dividend Yield
- EMN 3.19%
- SNN 3.01%
- EPS Growth
- EMN 52.51
- SNN 39.77
- EPS
- EMN 7.47
- SNN 0.35
- Revenue
- EMN $9,344,000,000.00
- SNN $5,642,000,000.00
- Revenue This Year
- EMN $3.15
- SNN $6.97
- Revenue Next Year
- EMN $4.31
- SNN $5.46
- P/E Ratio
- EMN $13.61
- SNN $34.83
- Revenue Growth
- EMN N/A
- SNN 5.48
- 52 Week Low
- EMN $80.71
- SNN $23.65
- 52 Week High
- EMN $114.50
- SNN $31.72
- Technical
- Relative Strength Index (RSI)
- EMN 41.49
- SNN 32.09
- Support Level
- EMN $100.11
- SNN $24.49
- Resistance Level
- EMN $103.09
- SNN $25.09
- Average True Range (ATR)
- EMN 2.09
- SNN 0.43
- MACD
- EMN -0.23
- SNN -0.06
- Stochastic Oscillator
- EMN 39.18
- SNN 19.77
About EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.